PEMBROLIZUMAB AS FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD-INELIGIBLE PATIENTS, ALLOWS SUBSEQUENT THERAPY, AND GIVES ADEQUATE SURVIVAL.

Category Primary study
Conference17th International Conference on Malignant Lymphoma
Year 2023
This article has no abstract
Epistemonikos ID: 21bd4921e613b05073f88a198e2ed45f44452637
First added on: May 18, 2026